Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Effect of increasing the infliximab dose in rheumatoid arthritis].

× No keyword cloud information.

12 in total

1. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245

2. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.

Authors: R F van Vollenhoven; S Brannemark; L Klareskog
Journal: Ann Rheum Dis Date: 2004-04 Impact factor: 19.103

3. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE.

Authors: R F van Vollenhoven; L Klareskog
Journal: Scand J Rheumatol Date: 2007 Nov-Dec Impact factor: 3.641

Review 4. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review.

Authors: R Ariza-Ariza; F Navarro-Sarabia; B Hernández-Cruz; L Rodríguez-Arboleya; V Navarro-Compán; J Toyos
Journal: Rheumatology (Oxford) Date: 2006-09-29 Impact factor: 7.580

5. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors: R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal: Lancet Date: 1999-12-04 Impact factor: 79.321

6. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.

Authors: M Flendrie; M C W Creemers; P L C M van Riel
Journal: Rheumatology (Oxford) Date: 2006-06-16 Impact factor: 7.580

7. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

Authors: A Finckh; J F Simard; C Gabay; P-A Guerne
Journal: Ann Rheum Dis Date: 2005-12-08 Impact factor: 19.103

8. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

Authors: E William St Clair; Désirée M F M van der Heijde; Josef S Smolen; Ravinder N Maini; Joan M Bathon; Paul Emery; Edward Keystone; Michael Schiff; Joachim R Kalden; Ben Wang; Kimberly Dewoody; Roberta Weiss; Daniel Baker
Journal: Arthritis Rheum Date: 2004-11

9. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.

Authors: Mahboob U Rahman; Ingrid Strusberg; Piet Geusens; Alberto Berman; David Yocum; Daniel Baker; Carrie Wagner; John Han; Rene Westhovens
Journal: Ann Rheum Dis Date: 2007-03-28 Impact factor: 19.103

10. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.

Authors: E William St Clair; Carrie L Wagner; Adedigbo A Fasanmade; Benjamin Wang; Thomas Schaible; Arthur Kavanaugh; Edward C Keystone
Journal: Arthritis Rheum Date: 2002-06